Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of bkm120 in relapsed and refractory nhl

Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Summary: this is a phase ii study evaluating the safety, tolerability and efficacy of bkm120 in patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl) or follicular lymphoma (fl).


Eligibility criteria:
inclusion criteria: 1. patient had a histologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma, or diffuse large b cell lymphoma. 2. patient had relapsed or refractory disease and received at least one prior therapy. 3. patient with diffuse large b cell lymphoma had received or was ineligible for autologous or allogeneic stem cell transplant. 4. patient had at least one measurable nodal lesion (≥2 cm) according to cheson criteria (cheson 2007). in case where the patient had no measurable nodal lesions ≥ 2 cm in the long axis at baseline, then the patient must have had at least one measurable extra-nodal lesion. 5. patient had an eastern cooperative oncology group (ecog) performance status ≤ 2. 6. patient had adequate bone marrow and organ function. exclusion criteria: 1. patient had received previous treatment with pi3k inhibitors 2. patient had evidence of graft versus host disease (gvhd). 3. patient had active or history of central nervous system (cns) disease. 4. patient had a concurrent malignancy or had a malignancy within 3 years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer). 5. patient had a score ≥ 12 on the phq-9 questionnaire. 6. patient had a gad-7 mood scale score ≥ 15. 7. pregnant or nursing women 8. patient who did not use highly effective contraception methods to avoid becoming pregnant or conceiving offspring.

Keywords: diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma, pi3k inhibitor, non-hodgkin lymphoma, nhl
applications of dual energy ct in patients with osseous metastases from castrate-resistant prostate cancer

Conditions: Dual Energy CT (DECT); Prostate Cancer

Summary: the purpose of this study is to establish a more accurate and precise way to image (take pictures of) metastatic bone disease in patients with prostate cancer for staging and monitoring response to therapy. more specifically, the study aims to evaluate the capabilities of dual energy ct as a more precise and accurate tool for staging and monitoring of therapy response in patients with osseous metastases from castrate-resistant prostate cancer. bone metastases in prostate cancer patients are a clinical and diagnostic challenge to image. sometimes very small metastatic bone lesions may only become detectable by imaging in response to therapy due to increased bone deposition during the first three months after therapy. commonly used imaging tests (such as regular ct or bone scan) are unable to reliably tell the difference between increased bone deposition (therapy response) and growth of the lesion (progressive disease). this diagnostic challenge may have profound negative effects on patient management since it may require additional imaging before an accurate determination of tumor response can be made. an appropriate determination of tumor response is needed for appropriate management of prostate cancer. the investigators anticipate that the new imaging tested in this study (called dual energy ct) may provide additional critical information in this clinical and diagnostic challenge. approximately 100 people with prostate cancer and metastatic bone disease will take part in this study. at enrollment, three months, and six months, they will will receive a non-enhanced (without contrast) dual energy ct scan of the chest, abdomen and pelvis before receiving their routine, clinical contrast-enhanced ct scan.


Eligibility criteria:
inclusion criteria: 1. oncology patients with castrate-resistant prostate cancer planned for therapy with abiraterone acetate or enzalutamide and prednisolone undergoing clinically indicated mdct (multi-detector computed tomography) of the chest, abdomen and pelvis 2. \> 18 years old 3. serum creatinine \< 2.0 4. bmi \< 35kg/m\^2 5. sign informed consent exclusion criteria: - history of anaphylactoid reaction to iodinated contrast material
local triamcinolone injection in active thyroid orbitopathy

Conditions: Thyroid Disease

Summary: comparing the effectiveness of subconjunctival and peribulbar triamcinolone injection to systemic steroid therapy for patients with active thyroid orbitopathy.

local steroid treatment may help in active thyroid orbitopathy. till today, systemic steroids are the treatment for active thyroid orbitopathy which is associated with systemic adverse effects. in this study the investigators want to compare the effectiveness of local triamcinolone therapy for active thyroid orbitopathy.

Eligibility criteria:
inclusion criteria: * age\>18 years. * active thyroid orbitopathy according to clinical activity score\>=3. exclusion criteria: * intraorbital or active infections. * tuberculosis. * other orbital disease. * pregnancy. * compressive optic neuropathy. * systemic steroid therapy within 6 months of study start.
phase 3 study of tavocept versus placebo in patients with newly diagnosed or relapsed advanced primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplatin

Conditions: Non-small Cell Lung Cancer

Summary: tavocept is an investigational drug that is being developed to see if it can increase the survival of patients who are being treated with chemotherapy as well as to see if it can prevent or reduce side effects of chemotherapy. this research study is aimed at trying to find out if people with advanced adenocarcinoma of the lung who are treated with a standard combination of chemotherapy drugs will live longer if they are also treated with an investigational drug called "tavocept." another objective of this research study is to find out whether or not tavocept helps to prevent or reduce side-effects like kidney damage, anemia, and nausea and vomiting that can occur with these drug combinations. the drug combinations that will be used in this research study will include either paclitaxel and cisplatin, or docetaxel and cisplatin. these drug combinations are approved to be used to treat people with advanced nsclc. every patient on this research study will be treated with standard chemotherapy for primary nsclc in the form of either docetaxel or paclitaxel (these will be recommended by your research study doctor), which will be given in combination with cisplatin.


Eligibility criteria:
inclusion criteria: * confirmed histopathological diagnosis of inoperable advanced primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung * no prior systemic treatment for non-small cell lung cancer including chemotherapy, immunotherapy, hormonal therapy, targeted therapies or investigational drugs exclusion criteria: * small cell, squamous cell, large cell or undifferentiated or any form of mixed (eg, small cell and adenocarcinoma or squamous and adenocarcinoma) histopathological or cytological diagnosis of primary lung cancer * adenocarcinoma arising from primary sites other than the lung * patients without documented stage 4 disease (in accordance with ajcc tmm staging system 7th edition) * patients with unstable cns mets within 21 days before randomization
blood microrna depression change after dhca

Conditions: Aortic Aneurysm

Summary: collect the blood sample per-operation experience deep hypothermia cardiac arrest for aorta artery replacement surgery collect the blood from the cpb machine and from intravenous injection tube which already set at different time point.

collect the blood sample per-operation experience deep hypothermia cardiac arrest for aorta artery replacement surgery collect the blood from the cpb machine and from intravenous injection tube which already set at different time point test the blood sample of dhca, analysis the correlation between mir-194 and temperature.

Eligibility criteria:
inclusion criteria: * aortic dissection patients exclusion criteria: * other organ disorder
laser versus ultrasonic lithotripsy in percutaneous nephrolithotomy for staghorn stones

Conditions: Kidney Stones

Summary: this study will be conducted to compare the results of laser and ultrasonic lithotripsy in disintegration of staghorn stones during percutaneous nephrolithotomy.

patients with complete staghorn stones who are eligible to percutaneous nephrolithotomy (pnl) will be randomized between two groups. group 1: will undergo laser lithotripsy during pnl group 2: will undergo ultrasonic lithotripsy during pnl

Eligibility criteria:
inclusion criteria: 1. complete staghorn stones (filling the renal pelvis and branching to 3 major calyces 2. age: 18-70 years exclusion criteria: 1. congenital renal anomalies such as horse shoe kidney. 2. contraindications to pnl such as bleeding tendency and uncontrolled hypertension. 3. associated pathological features requiring open intervention such as upjo 4. partial staghorn stones (filling the renal pelvis and branching to 2 major calyces) 5. giant staghorn stone (very large staghorn stone that branch and re-branch in hugely dilated calyceal system)

Keywords: staghorn stones percutaneous nephrolithotomy laser randomized trial lithotripsy
real world data collection and analysis on the anterior cervical spine surgery

Conditions: Cervical Disc Degeneration

Summary: this observational study aims to evaluate the efficacy and safety of anterior cervical spine surgery in patients with cervical degenerative disc disease

this observational study is an ambispective cohort designed. patients who are diagnosed cervical degenerative disc disease will be selected to join in this study. visual analogue scale, japanese orthopaedic association scale, neck disability index, sf-36, and device related or procedure related adverse events will be recorded and compared to evaluate the efficacy and safety of anterior cervical spine surgery in patients with cervical degenerative disc disease

Eligibility criteria:
inclusion criteria: 1. patients over 18 years old 2. clinical symptoms and imaging support cervical degenerative disc disease； 3. failed a minimum of 3months conservative treatment 4. have had (retrospective cohort) or the decision has been made to have (prospective cohort) anterior cervical spine surgery 5. written informed consent given by subject exclusion criteria: 1. patients with non-degenerative (e.g., trauma, tumor, and infection) or neuromuscular diseases (e.g., motor neuron disease) were excluded 2. patients with cervical spine x-ray film and ct scan contraindications 3. women who are lactating and pregnant

Keywords: cervical degenerative disease cervical myelopathy cervical radiculopathy anterior cervical spine surgery
compare the efficacy and the safety of taxotere and nanoxel m as neoadjuvant chemotherapy in breast cancer

Conditions: Breast Cancer

Summary: phase iii clinical trial to compare the efficacy and the safety of ac(doxorubicin, cyclophosphamide) followed by 4 cycles taxotere versus ac(doxorubicin, cyclophosphamide) followed by 4 cycles nanoxel m as neoadjuvant chemotherapy in patients with breast cancer

the purpose of this study is to evaluate efficacy and safety of ac followed by taxotere versus ac followed by nanoxel m as neoadjuvant chemotherapy in breast caner patients.

Eligibility criteria:
inclusion criteria: 1. patients who were diagnosed with primary breast cancer by core biopsy 2. patients who have been identified as her2 negative in the tissue obtained through core needle biopsy and have confirmed the positive / negative status of er (estrogen receptor) and progesterone receptor (pr) * her2 positive is defined as ihc 3+ or fish + 3. patinets whose tnm stage confirmed by ct or mri (t2-t3, anyn, m0 or t1-3, n1-3, m0) exclusion criteria: 1. patients who have distant metastasis 2. patients who have cystitis or urinary obstruction 3. patients who have history of thromboembolism or coagulation disorder 4. patients who have interstitial lung disease ans liver cirrhosis ( \> child-pugh class b) 5. patients who have insulin-dependent type ii diabete mellitus
covid-10 in the pediatric population: sars-cov-2 seropositivity

Conditions: SARS-CoV-2 Infection

Summary: the purpose of this study was to conduct an epidemiological survey of the pediatric population via sars cov-2 igg antibody testing in order to evaluate the incidence of asymptomatic infection and seropositivity among children and establish risk factors of infection and characterization of asymptomatic carriers. additionally, among seropositive children, antibody titers will be explored in order to reach a better understanding of the relationship between immunity over time after different types of initial exposures. methods study design and population a prospective epidemiological survey was conducted in the pediatric emergency department (ed) of the shaare zedek medical center, a tertiary medical center in jerusalem, israel, between october 2020 and january 2021. all patients presenting to the pediatric ed during the study period and requiring blood tests or and iv insertion for any clinical reason were considered eligible to participate in the study. the parents and/or legal guardians of these patients gave oral consent for an additional 1-3 ml of blood to be sent for sars-cov-2 antibody testing. in addition, all consenting parent/guardians filled out a comprehensive questionnaire regarding demographic background, past medical history, and specific covid-19 details such as exposures to carriers, past pcr testing, symptoms etc. all patients with positive serology results were contacted by phone and updated of the test results. laboratory testing all blood samples were collected in a clot-activator test tube. initial testing was conducted using the abbott sars-cov-2 igg assay. a positive result was considered a value above 1.5 with 0.8 - 1.4 cosidered grayzone results. all positive and grayzone results were then retested in the diasoren liaison® sars-cov-2 s1/s2 igg assay. statistical analysis statistical analysis was conducted using spss statistics for windows, version 25.0. armonk, ny: ibm corp. clinical variables were analyzed using the chi-squared test for categorical variables and the t-test for continuous variables. all statistical tests were two-way tests and p value of 5% or less was considered statistically significant.


Eligibility criteria:
inclusion criteria: * all patients presenting to the pediatric emergency department for any reason exclusion criteria: * none

Keywords: serology sars-cov-2 antibodies
effect of vachellia nilotica versus sodium hypochlorite as root canal irrigant on postoperative pain and bacterial load reduction in mandibular premolar teeth with necrotic pulp

Conditions: Necrotic Pulp; Post Operative Pain

Summary: the aim of this study is to assess the effect of v. nilotica extract solution versus 2.5% naocl on the intensity of postoperative pain and the amount of bacterial load reduction.

clinical compare the effect of v. nilotica extract solution versus 2.5% naocl on the intensity of postoperative pain and the amount of bacterial load reduction when used as root canal irrigant in necrotic pulp. the post operative pain will be recorded using numerical rating scale, and the bacterial load reduction will be measured by bacterial counting using agar culture technique.

Eligibility criteria:
inclusion criteria: 1. systemically healthy patient (asa i, ii). 2. age between 20 and 40 years. 3. male or female. 4. patient who is able to sign and comprehend the pain scale (committed patient). 5. mandibular single rooted premolars having the following criteria: * with single root canal. * diagnosed clinically with pulp necrosis. * absence of spontaneous pulpal pain. * positive pain on percussion denoting apical periodontitis. * slight widening of periodontal space or peri-apical radiolucency smaller than 3 mm (0-2mm). exclusion criteria: 1. medically compromised patients (asa iii or iv). 2. teeth with: * immature roots. * vital pulp tissues. * association with swelling. * acute peri-apical abscess or acute exacerbation of a chronic abscess. * mobility grade ii or iii. * previously accessed or endodontically treated. * deep periodontal pockets more than 4 mm. * vertical root fractures, coronal perforation, calcification, and external or internal root resorptions. 3. patients who could not interpret the nrs. 4. patients with diabetes, immune-compromising, and immunosuppression disease and pregnant women will be also excluded. 5. history of intolerance to nsaids.
implementation of genomics in substance use disorder treatment

Conditions: Tobacco Use Disorder; Smoking Cessation; Tobacco Use Cessation

Summary: cigarette smoking remains one of the leading causes of preventable death. effective smoking cessation medications exist but use of these treatments is low, making it difficult for most to quit smoking. behavioral interventions are needed to engage current smokers in the process of quitting smoking and promote the use of evidence-based cessation medications. at the same time, genetics influences one's smoking behaviors (e.g., how much they smoke, difficulty quitting) and risk of smoking-related diseases, yet these personalized factors have not been included in existing behavioral interventions. incorporating these individualized factors into smoking cessation interventions may make them more personally engaging and thus motivating for treatment. this study will pilot test a risk communication tool that is personalized to one's genetics and will demonstrate the feasibility of a larger trial to test the effect of this personalized genetically-informed intervention on smoking cessation.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * smoked combustible cigarettes in past 30 days * computer access for remote-based study visits exclusion criteria: * younger than 18 years of age * no computer access
nims- new implantable pump in pulmonary arterial hypertension, a safety follow up

Conditions: Pulmonary Hypertension Group 1 and 4 According to Nice Classification

Summary: this observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous lenuspro pump. how the surgical procedure is performed and the clinical follow-up of these patients. and by this also charting complications that might occur in relation to treatment. participating centres are located in denmark, norway and sweden.


Eligibility criteria:
inclusion criteria: * the patient should have been diagnosed with pulmonary arterial hypertension * the patient has received or will receive treatment with the implanted pump lenuspro exclusion criteria: * the patient is participating in another study which means treatment of the patient no longer follows the normal clinical practice
virtual for care atrial fibrillation patients using virtues

Conditions: Atrial Fibrillation

Summary: patients will atrial fibrillation, a type of irregular heart rhythm, frequently go to the emergency room in order to manage their condition. this study will use a chart review to look at the characteristics and frequency of atrial fibrillation patients who go to the emergency room. in addition to the chart review, patients with atrial fibrillation who have recently gone to the emergency room or have been hospitalized will be approached and asked if they want to use an electronic health care system that can be accessed by both themselves and their health care providers. along with the system, patients will be given a health canada approved heart rhythm sensor, so patients will be able to record their heart rhythm when they feel symptoms and send the information to the heart rhythm team. the heart rhythm team will then make real-time recommendations to the patient about how they can manage their rhythm and symptoms. patients will be asked to complete satisfaction and quality of life surveys. our goal is to provide efficient and effective care for patients with af, resulting in decreased repeat ed visits.

see brief summary.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * documented symptomatic new-onset or pre-existing, non-valvular af * er visit or hospitalization for primary af in the last 6 months * proficient in the english language exclusion criteria: * unable to provide informed consent * planning to move/relocate during the period of study * current pregnancy * patient is a prisoner/incarcerated * no access to a smart device with bluetooth capabilities * planned percutaneous coronary intervention, coronary artery bypass graphing or heart valve surgery within the next year * any medical condition making 1 year survival unlikely

Keywords: virtual care
the effect of a probiotic preparation (vsl#3) plus infliximab in children with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose was to evaluate as to whether administration of infliximab of 12 week interval with supplementary vsl#3 is more effective or at least of similar efficacy when compared to conventional administration of infliximab only of 8 week interval.

the purpose of our study was to evaluate if supplementation of vsl#3 can improve treatment outcome for those pediatric crohn's patients treated with infliximab every 12 weeks.

Eligibility criteria:
inclusion criteria: * pediatric patients who were diagnosed with severe crohn's disease who require infliximab treatment * confirmed diagnostic of crohn's disease in clinical, endoscopic and histological findings exclusion criteria: * patients who has proven to have infliximab antibody

Keywords: crohn's disease vsl #3 infliximab
dose-escalating study of lbh589 in adult patients with advanced solid tumors

Conditions: Cancer; Advanced Solid Tumor

Summary: this study will characterize the safety, tolerability, biological activity, and pharmacokinetics of lbh589 in japanese patients with advanced solid tumors whose disease has progressed despite standard therapies, or for whom no standard therapy exists.


Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically confirmed, advanced solid tumors whose disease has progressed despite available standard therapies, or for which no standard therapy exists. 2. at least one measurable or non-measurable lesion as defined by modified recist criteria for solid tumors 3. age ≥20 years old 4. world health organization (who) performance status of ≤2 5. patients must have the following laboratory values as defined in protocol 6. life expectancy of ≥ 12 weeks 7. written informed consent obtained exclusion criteria: 1. patients with evidence of cns tumor or metastasis 2. patients with pleural effusion and/or ascites to be drained 3. patients with any peripheral neuropathy ≥ ctcae grade 2 4. impaired cardiac function defined in protocol 5. acute or chronic liver or renal disease 6. other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol 7. patients who are currently receiving treatment with any of the medications which have the potential to prolong the qt interval and the treatment cannot be either discontinued or switched to a different medication 8. patients who have received chemotherapy ≤4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

Keywords: histone deacetylases hdac inhibitor lbh589 advanced solid tumor adult
the effect of metformin on the correlation between hyperinsulinemia and hypertension

Conditions: Diabetes Mellitus; Essential Hypertension

Summary: the objective of this study is to investigate the effect of metformin on the correlation between hyperinsulinemia and hypertension.


Eligibility criteria:
inclusion criteria: * 20 to 65 years of age, regardless of sex * duration of hypertension was \<5 years * overweight or obesity, mild to moderate hypertension, receive no euglycemic agent or antiobesity drug

Keywords: hypertension insulin resistance hyperinsulinemia metformin fosinopril